Clinical trials: Musculoskeletal and Connective Tissue Disorders
Rheumatoid Arthritis
Abatacept Versus Adalimumab Head-to-Head
The purpose of this study is demonstrate that subcutaneous abatacept is non-inferior (no worse than) to subcutaneous adalimumab in the treatment of subjects with rheumatoid arthritis who are biologic naive
- Trial name
- NCT00929864
- Testing
- Abatacept, Adalimumab
- Where
- 83 sites in United States, Argentina and 3 more
- Volunteers
- 869 people
- Sponsor
- Bristol-Myers Squibb
Rheumatoid Arthritis
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
This is a single-arm, multi-center, prospective cohort study (post-marketing observational study). The observation period for each participant is 48 weeks.
- Trial name
- NCT01346488
- Volunteers
- 2,088 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Rheumatoid Arthritis
A Study of CDP870 as Add-on Meditation to Methotrexate (MTX) in Patients With Rheumatoid Arthritis
The objective of this trial is to compare the efficacy of Certolizumab (CZP) (CDP870) in combination with Methotrexate (MTX) to MTX alone in the treatment of signs and symptoms in patients with active rheumatoid arthritis (RA)…
- Trial name
- NCT00993317
- Testing
- CDP870 200mg, Methotrexate
- Where
- 15 sites in South Korea
- Volunteers
- 127 people
- Sponsor
- Korea Otsuka Pharmaceutical Co., Ltd.
Psoriasis
A Long Term Study To Evaluate The Safety, Tolerability And Efficacy Of CP-690,550 In Patients With Moderate To Severe Plaque Psoriasis And/Or Psoriatic Arthritis
The main objective of this study is to evaluate the long term safety of CP-690,550 in patients being treated for moderate to severe plaque psoriasis and/or psoriatic arthritis.
- Trial name
- NCT01519089
- Testing
- CP-690,550, CP-690, 550
- Where
- 16 sites in Japan
- Volunteers
- 95 people
- Sponsor
- Pfizer
Rheumatoid Arthritis
Crossover Study of Safety and Tolerability of Two Formulations of Adalimumab.
This study will compare injection site pain levels between current Humira® formulation versus a new formulation of Humira in patients with Rheumatoid Arthritis (RA), who are either currently on a stable dose (minimum six…
- Trial name
- NCT01561313
- Testing
- Adalimumab
- Where
- 6 sites in Belgium, Czechia
- Volunteers
- 64 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Dermatomyositis
Ravulizumab Versus Placebo in Adult Participants With Dermatomyositis
This is a Phase 2/3, double-blind, randomized, placebo-controlled, parallel group, multicenter study to evaluate the efficacy, safety, pharmacokinetics, pharmacodynamics, and immunogenicity of ravulizumab in adult participants…
- Trial name
- NCT04999020
- Testing
- Ravulizumab
- Where
- 111 sites in United States, Australia and 11 more
- Volunteers
- 38 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Polyarticular Course Juvenile Idiopathic Arthritis
Efficacy and Safety Dose Finding Study of Givinostat to Treat Polyarticular Course Juvenile Idiopathic Arthritis
The present study has been designed in order to evaluate the efficacy and safety of two doses of Givinostat in subjects with polyarticular course JIA Givinostat ready-to-use suspension especially intended for paediatric…
- Trial name
- NCT01261624
- Testing
- Givinostat
- Where
- 13 sites in Belgium, Czechia and 5 more
- Volunteers
- 16 people
- Sponsor
- Italfarmaco
Rheumatoid Arthritis
Efficacy Confirmation Study of CDP870 in Early Rheumatoid Arthritis
The objective of this study is to assess the efficacy of certolizumab pegol (CZP) with methotrexate (MTX) compared with MTX-alone in patients with early-stage rheumatoid arthritis (RA) who are naive to MTX and have with poor…
- Trial name
- NCT01451203
- Testing
- CZP, methotrexate (MTX)
- Where
- 8 sites in Japan
- Volunteers
- 319 people
- Sponsor
- Astellas Pharma Inc
Knee Osteoarthritis
Wearable LITUS Device for Osteoarthritis of the Knee: a Randomized Double-Blind Placebo-Controlled Trial
The purpose of this study is to measure the effectiveness of a wearable therapeutic ultrasound device in patients with stage I and stage II knee osteoarthritis.
- Trial name
- NCT02083861
- Testing
- Sam Ultrasonic Diathermy Device
- Where
- United States
- Volunteers
- 93 people
- Sponsor
- ZetrOZ, Inc.
Rheumatoid Arthritis
A Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to DMARDs or Anti-TNF
This open-label, single arm study will evaluate the safety and efficacy of RoActemra/Actemra (tocilizumab) in patients with active, moderate to severe rheumatoid arthritis who have an inadequate response to disease-modifying…
- Trial name
- NCT01326962
- Testing
- tocilizumab [RoActemra/Actemra]
- Where
- 4 sites in Saudi Arabia
- Volunteers
- 28 people
- Sponsor
- Hoffmann-La Roche
Arthritis, Rheumatoid
A Study of CNTO 136 (Sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Anti-TNF-Alpha Therapy (SIRROUND-T)
The purpose of this study is to assess the efficacy of sirukumab as measured by the reduction of the signs and symptoms of rheumatoid arthritis (RA) in patients with active RA who are unresponsive or intolerant to treatment with…
- Trial name
- NCT01606761
- Testing
- Sirukumab
- Where
- 201 sites in United States, Argentina and 20 more
- Volunteers
- 878 people
- Sponsor
- Janssen Research & Development, LLC
Psoriatic Arthritis
Study to Demonstrate the Efficacy, Safety and Tolerability of Intravenous Secukinumab up to 52 Weeks in Subjects With Active Psoriatic Arthritis
The purpose of this study was to provide up to 52 weeks of efficacy, safety and tolerability data to support registration of intravenous (i.v.) secukinumab (Initial dose of 6 mg/kg at Baseline (BSL) followed thereafter with 3…
- Trial name
- INVIGORATE 2 (NCT04209205)
- Testing
- AIN457 6 mg/kg i.v., AIN457 3 mg/kg
- Where
- 80 sites in United States, Brazil and 13 more
- Volunteers
- 381 people
- Sponsor
- Novartis Pharmaceuticals
Marfan Syndrome
Comparison of Aliskiren vs Negative Controls on Aortic Stiffness in Patients With MFS
Marfan syndrome (MFS) is an inherited disorder of connective tissue with morbidity and mortality from aortic dilatation and dissection.
- Trial name
- NCT01715207
- Testing
- Aliskiren, Atenolol
- Where
- South Korea
- Volunteers
- 30 people
- Sponsor
- Samsung Medical Center
Chronic Graft vs Host Disease, Chronic Graft-Versus-Host Disease
Study of Baricitinib, a JAK1/2 Inhibitor, in Chronic Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation
Background: Chronic graft versus host disease (cGVHD) can affect people who had a hematopoietic stem cell transplant using donor cells. It is often fatal. It is usually treated with high doses of steroids.
- Trial name
- NCT02759731
- Testing
- Baricitinib
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
Tenosynovial Giant Cell Tumor
A Study of the Efficacy and Safety of Pexidartinib in Adult Subjects With TGCT
This study will assess pexidartinib in adult participants with symptomatic TGCT that is associated with severe morbidity or functional limitations and not amendable to improvement with surgery.
- Trial name
- PLX3397 (NCT04488822)
- Testing
- Pexidartinib
- Where
- 9 sites in China, Taiwan
- Volunteers
- 40 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Early Rheumatoid Arthritis
Study to Determine the Effects of Different Doses of Methotrexate (MTX) When Taken With Adalimumab in Subjects With Early Rheumatoid Arthritis (RA)
The purpose of this study is to determine the effects of different doses of methotrexate (MTX) when taken with adalimumab in subjects with early rheumatoid arthritis (RA).
- Trial name
- CONCERTO (NCT01185301)
- Testing
- adalimumab, methotrexate
- Where
- 68 sites in United States, Argentina and 8 more
- Volunteers
- 395 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Rheumatoid Arthritis
PPAR-gamma Agonists, Rheumatoid Arthritis and Cardiovascular Disease
Patients with rheumatoid arthritis have a significantly higher risk to develop heart attacks and other complications of their blood vessels. New therapies are needed to prevent this complication.
- Trial name
- RAPPAR (NCT00554853)
- Testing
- pioglitazone, Sublingual nitroglycerine
- Where
- United States
- Volunteers
- 143 people
- Sponsor
- University of Michigan
Sjogren's Syndrome
Pilot Study of Raptiva to Treat Sjogren's Syndrome
This study will examine the effect of the drug Raptiva (efalizumab) in patients with Sjögren's syndrome (SS), an autoimmune disease affecting the glands producing saliva \& tears.
- Trial name
- NCT00344448
- Testing
- Raptiva
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- National Institute of Dental and Craniofacial Research (NIDCR)
Rheumatoid Arthritis
Magnetic Resonance Image Verified Early Response to Certolizumab Pegol in Subjects With Active Rheumatoid Arthritis (RA)
Phase IIIb study to determine early response to Certolizumab Pegol (CZP) with Magnetic Resonance Imaging (MRI) score Outcome Measures in Rheumatoid Arthritis (RA) Clinical Trials (OMERACT) RA MRI Scoring System (RAMRIS) in…
- Trial name
- MARVELOUS (NCT01235598)
- Testing
- Certolizumab Pegol (CZP) 200 mg, Certolizumab Pegol (CZP) 400 mg
- Where
- 10 sites in Denmark, Netherlands and 2 more
- Volunteers
- 41 people
- Sponsor
- UCB Pharma
Rheumatoid Arthritis
An Efficacy and Safety Study of CNTO 148 Subcutaneous Injection Compared With Placebo in Patients With Active Rheumatoid Arthritis
Multicenter, randomized, double-blind, placebo-controlled, 5-arm, dose-ranging study to assess the efficacy of subcutaneous injections of Golimumab (CNTO 148), 50 or 100 mg, at either 2- or 4- week intervals in subjects with…
- Trial name
- NCT00207714
- Testing
- Golimumab, MTX, Infliximab
- Volunteers
- 172 people
- Sponsor
- Centocor, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.